With its discovery of small molecules that activate RNA methylation, the biotech has broken new ground in epitranscriptomics. This breakthrough positions Chemestmed to advance candidates with the ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene, a key regulator of cell cycle progression that has been challenging to target with traditional therapies.

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in ...

NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics ...

LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, has appointed Norbert Bischofberger, Ph.D., as a Non-Executive Director to its Board of ...

UK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed up with the London-based startup to develop its small, activating ...